肝癌患者血清GLS含量  

Detection of serum gangliosides of patients with hepatocarcinoma

作　　者：王天然[1] 许爱国 周纬[1] 李丽萍 蒋燕[1] 张丽华 白小红[1] 马布仁[1] 

机构地区：[1]成都军区总医院临床实验中心,四川成都610083 [2]解放军第519医院,四川西昌615000

出　　处：《西南国防医药》2004年第5期485-487,共3页Medical Journal of National Defending Forces in Southwest China

摘　　要：目的 :研究肝癌患者血清GLS含量及其临床意义。方法 :测定肝癌、非癌肝病患者和健康人GLS ,然后分组统计。结果 :肝癌组GLS(799± 2 2 6mg/L)显著高于健康组 (4 6 6± 6 5mg/L)和各良性肝病组 ;各良性肝病组与健康组无明显差异。测定GLS对肝癌诊断敏感度、特异度、准确度和诊断效率分别为 82 4 %、94 7%、89 7%和 78 0 % ,具有显著临床应用价值 ,并且高于血清AFP测定。测定GLS与AFP联合应用诊断价值更为显著。结论 :肝癌患者血清GLS显著增加 ;其测定对肝癌诊断、病情及疗效监测、预后分析具有显著临床价值 ;Objective: To study the level of serum gangliosides(GLS) of patients with hepatocarcinoma and its clinical significance. Methods: The levels of serum GLS of healthy people and patients with hepatocarcinoma and other liver diseases were determined and the results were compared with each other. Results: The level of serum GLS of hepatocarcinoma group(799±226 mg/L) was higher significantly than that of the healthy group(466±65 mg/L) and other liver diseases group, but there was not difference of serum GLS between the healthy group and other liver diseases group. In diagnosis of hepatocarcinoma, the sensitivity, specificity, accuracy and diagnostic efficiency of GLS were 82.4%, 94.7%, 89.7% and 78.0%, respectively, and these rates were higher than those of serum AFP. The combination of determining GLS with AFP was more significant than either GLS or AFP in diagnosis of hepatocarcinma. Conclusion: Serum GLS of the patients with hepatocarcinma increase remarkably. Determining GLF will be helpful to diagnosis of hepatocarcinma, evaluation of the therapeutic effect and prognosis of this disease.

关 键 词：肝癌 血清GLS含量 肿瘤 肝病 甲胎蛋白 肝硬化 

分 类 号：R735.7[医药卫生—肿瘤]